CAMBRIDGE, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization application (MAA) the company submitted on July 10, 2006 for Hemopure® [hemoglobin glutamer - 250 (bovine)] for the treatment of acutely anemic adult orthopedic surgery patients under 80 years of age. Validation signifies that the application is complete and has been accepted for review.
